InterLink AI was first venture-funded in 2013 with a driving purpose to reduce the margin of human error in the dispensing of prescription medications in retail pharmacies, long-term care facilities and hospitals.
Our identRx™ and medPass™ solutions use 360-degree imaging and machine learning technology to learn, count, verify and dispense medications. Coupled with our veriFill™ telepharmacy software, pharmacists can confidently approve prescription fills from a remote location.
Ensuring ease, accuracy and safety in the prescription pick-up process is also a priority. Our unique scripClip™ will-call system connects with the existing pharmacy management and point-of-sale systems to make sure every customer quickly gets the right prescription and pharmacy staff is spending their valuable time where it’s most needed.
With this suite of data-driven solutions and relentless commitment to innovation, InterLink AI is helping improve patient outcomes by making pharmacy experiences easier – for staff and customers alike.
President and Chief Executive Officer
Dan Gordon brings over 30 years of experience in businesses ranging from healthcare private capital management to consulting, revenue cycle management and advertising. He has held roles in business development, strategy, customer experience, product management, organizational development, sales, marketing, and mergers and acquisitions. He has also started, operated and sold several businesses.
Dan is a sought-after keynote speaker, author and frequent contributor of thought leadership on customer experience and employee experience at numerous industry events. He is a founding member of the Omaha Customer Experience Professionals Association, and he has consulted with various organizations on corporate strategy, organizational development and business development. He is a graduate from the University of Notre Dame with a degree in Finance and Business Economics and a minor in Psychology. In addition to being a fitness junkie, Dan spends his free time with his wife chasing their three boys around the country to watch their collegiate sporting events.
Chief Financial Officer
Rolland “Rollie” Johns brings 30 years of experience to his role as chief financial officer at InterLink AI, with a strategic growth mindset and experience in finance, accounting, risk management, treasury and investor relations.
Rollie most recently served as executive vice president and chief financial officer at CSG Systems International, Inc., one of the world’s leading providers of revenue management, customer engagement and payments solutions, where he helped transform capital allocation, budgeting, business risk, financial reporting and mergers and acquisitions (M&A) processes and drive $1B+ in revenue. Prior to that, he spent more than 20 years at KPMG – providing professional services to large public and private sector companies around the world.
Rollie earned a Bachelor of Accountancy degree from University of San Diego. He actively serves the community as treasurer on the Habitat for Humanity of Omaha Board of Directors and has been a chairperson for a number of other nonprofit organizations and fundraising events, including Miami University Parents Counsel, INROADS, St. Wenceslaus Catholic Church, Archdiocese of Omaha and Duchesne Academy. Rollie and his wife raised three wonderful daughters and reside in Omaha, Nebraska.
Vice President of Pharmacy
Terry Cater has decades of experience managing pharmacies in large, publicly traded corporations, as well as numerous startups and independent pharmacies. He served as an independent pharmacy and healthcare consultant, as a director of pharmacy at Safeway and Save Mart, and as a vice president at both McKesson Corporation and Cardinal Health.
Terry is a registered pharmacist in the states of California, Nevada and Hawaii. He is a member of the California Pharmacists Association and the National Community Pharmacists Association and has served on a number of advisory boards.
Terry earned a Bachelor of Science in Pharmacy from the University of the Pacific and an M.B.A. from Saint Mary’s College of California.
Vice President of Information Technology (IT) and Engineering
Rob Thomas is a global IT Senior Executive with over 20 years’ experience building and executing best-in-class technology solutions. He is skilled in the fields of software development, engineering innovation and information strategy.
In his career as an IT executive, Rob worked for a large nonprofit organization in Kansas City which gave him an unparalleled perspective of leading a large, multi-faceted international team, as he led the largest technical overhaul their 60-year history, impacting over 400 global locations and expanding the technical proficiencies of over 1,800 employees internationally. He also founded Peerhouse, an IT consulting firm, which served former clients, including McDonald’s, Dell, US Air Force and Academy Bank, among others. Rob received his Bachelor of Science in Business and Finance/Human Resources from the University of Nebraska-Lincoln.
Associate Vice Chancellor of Business Development and Professor of Pathology & Microbiology at the University of Nebraska Medical Center
Rodney S. Markin previously spent 12 years as the Chairman, President and CEO of UNMC Physicians and served as the Interim Dean of the College of Medicine at UNMC. Dr. Markin’s professional and academic research interests have focused on clinical laboratory automation, which include but are not limited to, robotics, information systems, medical utilization management and outcomes optimization.
Dr. Markin received his Bachelor’s Degree in chemistry with a minor in mathematics and physics from Nebraska Wesleyan University in 1977; his Doctor of Philosophy (Ph.D.- biochemistry) from the University of Nebraska-Lincoln in 1980; his Doctor of Medicine (M.D.) degree from the University of Nebraska Medical Center (Omaha) in 1983. Dr. Markin completed his residency in pathology and laboratory medicine at the University of Nebraska Medical Center. Dr. Markin is board certified in Anatomic and Clinical Pathology.
Dr. Markin founded LAB-InterLink, a spin-out of the University of Nebraska Medical Center that provided products for hospital-based laboratory automation systems. He served as CEO of the company and provided the early funding to grow the business.
Partner & Chief Financial Officer, New Science Ventures
Tom Lavin is a co-founder of New Science Ventures and its Chief Financial Officer, responsible for financial, legal and administrative matters. He serves on the Board of Directors for Achronix Semiconductor Corporation, Light Sciences Oncology, and RF Arrays, Inc. and is an observer on the boards of Vorago, Juventas Therapeutics, Therox and Directed Sensing. He formerly served on the Board of Celleration (acquired by Aliqua). Prior to NSV, he was a senior professional in finance and investment banking for over 30 years. Tom has extensive experience in private and public equity and debt transactions, mergers and acquisitions and financial restructurings in the U.S. and abroad. He was head of real estate investment banking at First Boston and Smith Barney and head of commercial mortgage lending at MetLife. Tom holds an A.B. degree in Government from Wesleyan University and an M.B.A. from Harvard Business School.
Bob has 32 years of healthcare venture capital investing experience including active involvement with 38 start-up or early stage companies, of which 32 achieved an IPO or successful merger. Prior to his VC activities, Bob started two companies of his own, one of which was a diagnostics lab and the other was a diagnostic product company. Bob also held an academic professorship at the University of Delaware, as well as being the Director of Technology at Becton Dickinson.
Prior to joining Latterell Venture Partners, Bob was a partner at Alliance Technology Ventures where he invested exclusively in healthcare ventures. Before ATV he was the original healthcare partner at the Sprout Group (the venture affiliate of Donaldson, Lufkin & Jenrette), and prior to Sprout he was the President of Merrill Lynch Venture Capital and Merrill Lynch R&D Management Inc. He also has served for many years as the Board Chair at the Keck Graduate Institute of Applied Life Sciences at the Claremont Colleges.
Bob holds a Ph.D. and an M.S. in chemistry from Purdue University where he was a Smith Kline Fellow, and he received his B.S. in physics from the University of Illinois at Urbana where he was a James Scholar.
Partner, Latterell Venture Partners
Jim brings more than 25 years of pharmaceutical research and management experience to LVP. In addition to his duties at LVP, Jim is currently chairman of Oncomed Pharmaceuticals, where he previously served as the founding CEO and helped organize the formation of the company. Jim was formerly President of Roche Bioscience in Palo Alto, CA. where he had responsibility for all bioscience research and development, ranging from genetics and genomics to clinical development of numerous new pharmaceuticals. Previously, Jim served as Chief Scientific Officer and Senior Vice President of R & D for Centocor, where he was responsible for the discovery and early clinical development of antibody and peptide-based therapeutic products. While at Centocor, Jim developed Remicade, the first of the TNF inhibitor biologics, as well as ReoPro, a novel platelet blocking drug used in conjunction with angioplasty.
Prior to Centocor, Jim served as Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service.
Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. Jim has authored or co-authored over 140 publications.